6533b7d8fe1ef96bd126b618

RESEARCH PRODUCT

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

Gary S. FriedmanNervin LawendyAndrew John ThorpeDeborah A WoodworthM ChioreanChinyu SuD S ChapmanA. OrlandoKatsuyoshi MatsuokaChudy I. NduakaR Cohen

subject

medicine.medical_specialtyTofacitinibOctave (poetry)business.industryOPEN LABEL TREATMENTGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisMaintenance therapyInternal medicinemedicineIn patientbusinesshttps://doi.org/10.1093/ecco-jcc/jjy222.075